Paolo Abada

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Medicine, Oncology, Pharmacology +9

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown et al. · New England Journal of Medicine · 2023 · 217 citations · Full text

Medicine, Oncology, Pharmacology +15

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

Michael Wang, Wojciech Jurczak, Pier Luigi Zinzani et al. · Journal of Clinical Oncology · 2023 · 106 citations · Full text

Medicine, Hematology, Pharmacology +16

REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · Journal of Clinical Oncology · 2018 · 96 citations

Medicine, Oncology, Pharmacotherapy +16

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Ari David Baron, Peter Malfertheiner et al. · JAMA Oncology · 2016 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +16